InvestorsHub Logo
Followers 33
Posts 5264
Boards Moderated 0
Alias Born 01/23/2019

Re: TalShu post# 413837

Saturday, 08/12/2023 2:43:47 PM

Saturday, August 12, 2023 2:43:47 PM

Post# of 424141
Tal, I happened to stop by Ihub to see if anything new. After reading your post I tried to find the agreement between amrn and Mochida see below for the only exhibit I could locate.

https://www.sec.gov/Archives/edgar/data/897448/000119312518189948/d602525dex991.htm

Also, an excerpt from 10K 2018. It appears that somewhere a collaborative agreement does exist. I'll continue to research

In June 2018, we entered into a multi-faceted collaboration with Mochida related to the development and commercialization of drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. Among other terms in the agreement, we obtained an exclusive license to certain Mochida intellectual property to advance our interests in the United States and certain other territories and the parties will collaborate to research and develop new products and indications based on EPA for our commercialization in the United States and certain other territories. The potential new product and indication opportunities

74



contemplated under this agreement are currently in early stages of development. Upon closing of the collaboration agreement, we made a non-refundable, non-creditable upfront payment of approximately $2.7 million. In addition, the agreement provides for milestone payments from us upon the achievement of certain product development milestones and royalties on net sales of future products arising from the collaboration, if any. Expenditures related to research and development activities for product candidates under the collaboration agreement were immaterial in 2018 and are expected to be less than $5.0 million in 2019.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News